Dupilumab

29 trials 13 recruiting DDermatology

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

13 Recruiting

14 Completed trials

14 Sponsors

19 Countries

Phase III

Phase II

Phase IV

Phase III: 8 Phase II/III: 1 Phase II: 3 Phase III/IV: 2 Phase IV: 15

Oversight events:

1 urgent safety measure 1 corrective measure across 2 trials

View oversight register →

Indications tested

Asthma 4 Chronic rhinosinusitis with nasal polyps 3 Neurodermatitis 2 Dermatitis atopic 2 Pruritus 1 Dermatitis 1 Chronic rhinosinusitis without nasal polyps 1 Wheezing 1 Eosinophilic gastritis 1 Systemic mastocytosis 1 Chronic obstructive pulmonary disease 1

Sponsors using this IMP

Sanofi-Aventis Recherche & Developpement 5 Medical University Of Vienna 4 Regeneron Pharmaceuticals Inc. 4 Rigshospitalet 3 AbbVie Deutschland GmbH & Co. KG 2 Amsterdam UMC 2 Centre Hospitalier Universitaire De Nantes 2 Hospital Universitario La Paz 1 Janssen - Cilag International 1 Klinikum rechts der Isar der TU Muenchen AöR 1 Medical University Of Gdansk 1 Sanofi-Aventis Research & Development 1

All trials — page 2

29 total

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Phase II 3 countries Janssen Cilag International
Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory… Ended

2023-509815-10-00 Phase IV 1 country Medical University Of Vienna
A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSw… Ended

2023-504014-30-00 Phase IV 1 country UZ Leuven
An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects… Ended

2024-515534-32-00 Phase II 1 country Klinikum rechts der Isar der TU Muenchen AöR
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended

2024-510745-34-00 Phase II/III 4 countries Regeneron Pharmaceuticals Inc.

Showing 25–29 of 29 trials

← All drugs A–Z